<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2006</study_start_year><condition>untreated patients with advanced colorectal cancer.</condition><condition>Colorectal cancer stage IV</condition><disease>Colorectal Cancer Stage Iv</disease><disease>Untreated Patients With Advanced Colorectal Cancer.</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2519979</full_dataset_link><location>Italy</location><study_start_month>6</study_start_month><keyword>LEDERFOLIN*EV 1FL LIOF 175MG</keyword><keyword>CAMPTO*1FL 100MG/5ML</keyword><keyword>FLUOROURACILE TEVA*IV FL 5G</keyword><keyword>AVASTIN*INFUS 1FL 100MG</keyword><repository>ECRIN MDR</repository><study_status>Ongoing</study_status></additional><is_claimable>false</is_claimable><name>Bevacizumab+folfiri in untreated patients with advanced colorectal cance</name><description>Primary objectives: Objectively confirmed response rate 
Time-to- progression</description><dates><creation>2006-06-15</creation></dates><accession>2519979</accession><cross_references><EU Clinical Trials Register>2006-002887-25</EU Clinical Trials Register></cross_references></HashMap>